"Tumor Stem Cell Assay" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents.
| Descriptor ID |
D014410
|
| MeSH Number(s) |
E01.370.225.500.383.910 E01.370.225.500.388.930 E05.200.500.383.910 E05.200.500.388.930 E05.242.383.910 E05.242.417.500 E05.337.550.200.800
|
| Concept/Terms |
Tumor Stem Cell Assay- Tumor Stem Cell Assay
- Colony Forming Units Assay, Tumor
- Neoplasm Stem Cell Assay
- Stem Cell Assay, Tumor
- Clonogenic Cell Assay, Tumor
- Colony-Forming Units Assay, Tumor
|
Below are MeSH descriptors whose meaning is more general than "Tumor Stem Cell Assay".
Below are MeSH descriptors whose meaning is more specific than "Tumor Stem Cell Assay".
This graph shows the total number of publications written about "Tumor Stem Cell Assay" by people in this website by year, and whether "Tumor Stem Cell Assay" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 1 | 2 |
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 3 | 3 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Stem Cell Assay" by people in Profiles.
-
KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer. Neoplasia. 2014 Aug; 16(8):644-55.
-
miR-138 overexpression is more powerful than hTERT knockdown to potentiate apigenin for apoptosis in neuroblastoma in vitro and in vivo. Exp Cell Res. 2013 Jun 10; 319(10):1575-85.
-
MicroRNA-510 promotes cell and tumor growth by targeting peroxiredoxin1 in breast cancer. Breast Cancer Res. 2013; 15(4):R70.
-
Lycopene synergistically enhances quinacrine action to inhibit Wnt-TCF signaling in breast cancer cells through APC. Carcinogenesis. 2013 Feb; 34(2):277-86.
-
A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors. Cancer Res. 2011 Nov 01; 71(21):6836-47.
-
Synergistic anticancer effects achieved by co-delivery of TRAIL and paclitaxel using cationic polymeric micelles. Macromol Biosci. 2011 Feb 11; 11(2):296-307.
-
Knockdown of hTERT and concurrent treatment with interferon-gamma inhibited proliferation and invasion of human glioblastoma cell lines. Int J Biochem Cell Biol. 2010 Jul; 42(7):1164-73.
-
Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg. 2004 Oct; 78(4):1207-14; discussion 1207-14.
-
Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel. Biol Blood Marrow Transplant. 2003 Jun; 9(6):364-72.
-
INI1 expression induces cell cycle arrest and markers of senescence in malignant rhabdoid tumor cells. J Cell Physiol. 2003 Mar; 194(3):303-13.